Mayne Pharma Group Limited (MAYNF)
USD 4.25
(-2.3%)
USD 4.25
(-2.3%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 | 74.62 Million AUD | -9.76% |
| 2023 | 82.7 Million AUD | -24.06% |
| 2022 | 108.9 Million AUD | 6.24% |
| 2021 | 102.51 Million AUD | 9.06% |
| 2020 | 93.99 Million AUD | -6.33% |
| 2019 | 100.34 Million AUD | 22.14% |
| 2018 | 82.15 Million AUD | -22.78% |
| 2017 | 106.39 Million AUD | 173.2% |
| 2016 | 38.94 Million AUD | 73.51% |
| 2015 | 22.44 Million AUD | 30.22% |
| 2014 | 17.23 Million AUD | 26.8% |
| 2013 | 13.59 Million AUD | 87.64% |
| 2012 | 7.24 Million AUD | 12.78% |
| 2011 | 6.42 Million AUD | -1.18% |
| 2010 | 6.49 Million AUD | 0.0% |
| 2009 | - AUD | 0.0% |
| 2008 | - AUD | 0.0% |
| 2007 | - AUD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q3 | 74.62 Million AUD | -18.8% |
| 2024 Q4 | 74.62 Million AUD | 0.0% |
| 2024 Q2 | 91.9 Million AUD | 0.0% |
| 2024 FY | 74.62 Million AUD | -9.76% |
| 2024 Q1 | 91.9 Million AUD | -15.61% |
| 2023 Q2 | 125.31 Million AUD | 0.0% |
| 2023 FY | 82.7 Million AUD | -24.06% |
| 2023 Q1 | 125.31 Million AUD | 15.07% |
| 2023 Q4 | 108.9 Million AUD | 31.69% |
| 2023 Q3 | 82.7 Million AUD | -34.01% |
| 2022 Q2 | 111.88 Million AUD | 0.0% |
| 2022 Q4 | 108.9 Million AUD | 0.0% |
| 2022 FY | 108.9 Million AUD | 6.24% |
| 2022 Q3 | 108.9 Million AUD | -2.66% |
| 2022 Q1 | 111.88 Million AUD | 9.14% |
| 2021 Q1 | 95.4 Million AUD | 1.5% |
| 2021 FY | 102.51 Million AUD | 9.06% |
| 2021 Q2 | 95.4 Million AUD | 0.0% |
| 2021 Q4 | 102.51 Million AUD | 0.0% |
| 2021 Q3 | 102.51 Million AUD | 7.45% |
| 2020 Q4 | 93.99 Million AUD | 0.0% |
| 2020 FY | 93.99 Million AUD | -6.33% |
| 2020 Q2 | 93.34 Million AUD | 0.0% |
| 2020 Q3 | 93.99 Million AUD | 0.7% |
| 2020 Q1 | 93.34 Million AUD | -6.98% |
| 2019 Q4 | 100.34 Million AUD | 0.0% |
| 2019 FY | 100.34 Million AUD | 22.14% |
| 2019 Q3 | 100.34 Million AUD | -0.29% |
| 2019 Q1 | 100.64 Million AUD | 22.5% |
| 2019 Q2 | 100.64 Million AUD | 0.0% |
| 2018 Q4 | 82.15 Million AUD | 0.0% |
| 2018 Q2 | 88.58 Million AUD | 0.0% |
| 2018 FY | 82.15 Million AUD | -22.78% |
| 2018 Q1 | 88.58 Million AUD | -16.74% |
| 2018 Q3 | 82.15 Million AUD | -7.26% |
| 2017 Q3 | 106.39 Million AUD | -2.26% |
| 2017 Q2 | 108.85 Million AUD | 0.0% |
| 2017 Q4 | 106.39 Million AUD | 0.0% |
| 2017 Q1 | 108.85 Million AUD | 179.51% |
| 2017 FY | 106.39 Million AUD | 173.2% |
| 2016 FY | 38.94 Million AUD | 73.51% |
| 2016 Q1 | 28.62 Million AUD | 27.53% |
| 2016 Q4 | 38.94 Million AUD | 0.0% |
| 2016 Q3 | 38.94 Million AUD | 36.05% |
| 2016 Q2 | 28.62 Million AUD | 0.0% |
| 2015 Q3 | 22.44 Million AUD | 12.36% |
| 2015 Q2 | 19.97 Million AUD | 0.0% |
| 2015 FY | 22.44 Million AUD | 30.22% |
| 2015 Q4 | 22.44 Million AUD | 0.0% |
| 2015 Q1 | 19.97 Million AUD | 15.89% |
| 2014 FY | 17.23 Million AUD | 26.8% |
| 2014 Q2 | 17.18 Million AUD | 0.0% |
| 2014 Q3 | 17.23 Million AUD | 0.33% |
| 2014 Q4 | 17.23 Million AUD | 0.0% |
| 2014 Q1 | 17.18 Million AUD | 26.39% |
| 2013 FY | 13.59 Million AUD | 87.64% |
| 2013 Q3 | 13.59 Million AUD | 0.0% |
| 2013 Q4 | 13.59 Million AUD | 0.0% |
| 2012 Q4 | 7.24 Million AUD | 0.0% |
| 2012 FY | 7.24 Million AUD | 12.78% |
| 2011 FY | 6.42 Million AUD | -1.18% |
| 2011 Q4 | 6.42 Million AUD | 0.0% |
| 2010 Q4 | 6.49 Million AUD | 0.0% |
| 2010 FY | 6.49 Million AUD | 0.0% |
| 2009 Q4 | - AUD | 0.0% |
| 2009 FY | - AUD | 0.0% |
| 2008 FY | - AUD | 0.0% |
| 2008 Q4 | - AUD | 0.0% |
| 2007 FY | - AUD | 0.0% |
| 2007 Q4 | - AUD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| AstraZeneca PLC | 5.41 Billion USD | 98.622% |
| Bristol-Myers Squibb Company PFD CONV 2 | 2.66 Billion USD | 97.197% |
| CSPC Pharmaceutical Group Limited | 442.43 Million USD | 83.132% |
| Clarus Therapeutics Holdings, Inc. | 14.21 Million USD | -425.039% |
| Novartis AG | 5.91 Billion USD | 98.738% |
| PT Kalbe Farma Tbk. | 451.27 Million USD | 83.463% |